Literature DB >> 7857719

Protease inhibitors: role and potential therapeutic use in human cancer.

Y A DeClerck1, S Imren.   

Abstract

Proteases and protease inhibitors have been increasingly recognised as important factors in the physiopathology of human diseases, and our understanding of their role in cancer has dramatically increased over the last decade. We have obtained causal evidence linking proteases to tumour invasion and metastasis, and have become aware of genuine mechanisms used by tumour cells to optimise the use of proteases in the pericellular matrix. Many synthetic and natural inhibitors of these proteases have also been characterised, and their mechanisms of interaction with their corresponding enzymes are progressively unveiled as the X-ray crystal structures of these enzymes and their inhibitors are now reported. It has also become evident that many of these inhibitors, in addition to preventing the dissemination of cancer cells, have an inhibitory effect on tumour growth. Thus protease inhibitors are emerging as potentially therapeutic tools to treat cancer. In this article, recent studies on the role of proteases and their inhibitors in cancer are reviewed, and current ideas on their potential use as therapeutic agents are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7857719     DOI: 10.1016/0959-8049(94)00460-m

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  25 in total

1.  Role of integrin alpha(v)beta3 in the early phase of liver metastasis: PET and IVM analyses.

Authors:  Hironori Kikkawa; Masako Kaihou; Natsuko Horaguchi; Takayuki Uchida; Hidetoshi Imafuku; Ayano Takiguchi; Yukako Yamazaki; Chieko Koike; Ryoko Kuruto; Takeharu Kakiuchi; Hideo Tsukada; Yoshikazu Takada; Nariaki Matsuura; Naoto Oku
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

2.  Peptidyl vinyl sulphones: a new class of potent and selective cysteine protease inhibitors: S2P2 specificity of human cathepsin O2 in comparison with cathepsins S and L.

Authors:  D Brömme; J L Klaus; K Okamoto; D Rasnick; J T Palmer
Journal:  Biochem J       Date:  1996-04-01       Impact factor: 3.857

Review 3.  Matrix metalloproteinase inhibitors: present achievements and future prospects.

Authors:  L J Denis; J Verweij
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

4.  Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma.

Authors:  G Sehgal; J Hua; E J Bernhard; I Sehgal; T C Thompson; R J Muschel
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

5.  Matrix metalloproteinase inhibition improves survival in an orthotopic model of human pancreatic cancer.

Authors:  E E Zervox; M G Franz; K F Salhab; A E Shafii; J Menendez; W R Gower; A S Rosemurgy
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

Review 6.  Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle.

Authors:  Lea M Beaulieu; Brandi R Whitley; Theodore F Wiesner; Sophie M Rehault; Diane Palmieri; Abdel G Elkahloun; Frank C Church
Journal:  Bioessays       Date:  2007-10       Impact factor: 4.345

7.  Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells.

Authors:  Hiromichi Nakabayashi; Toshio Yawata; Keiji Shimizu
Journal:  BMC Cancer       Date:  2010-06-29       Impact factor: 4.430

Review 8.  Matrix metalloproteinase inhibitor development and the remodeling of drug discovery.

Authors:  J Thomas Peterson
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

9.  Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice.

Authors:  Angélica M Santos; Jason Jung; Nazneen Aziz; Joseph L Kissil; Ellen Puré
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

10.  Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer.

Authors:  S M Pulukuri; B Gorantla; J A Knost; J S Rao
Journal:  Oncogene       Date:  2009-06-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.